HK Stock Market Move | CSPC PHARMA (01093) rose nearly 6% after successively disclosing multiple R&D developments, covering areas such as mRNA tumor vaccines and recombinant protein vaccines.

CSPC PHARMA (01093) rose nearly 6%, up 5.86% as of press time, at HK$10.03, with a turnover of HK$402 million. On the news front, from September 28 to 29, CSPC PHARMA successively disclosed multiple R&D developments, covering areas such as mRNA tumor vaccines, recombinant protein vaccines, and obesity treatment. On September 29, CSPC PHARMA announced that its developed Class 1 preventive biological product new drug, recombinant shingles vaccine (SYS6052), has received approval from the U.S. FDA to conduct related clinical research in the United States. On the same day, the company also announced that the Phase Ib clinical trial (JMT206-003) of its developed JMT206 injection for weight management in overweight or obese adult patients has officially been initiated at the first research center in China. Earlier, on the evening of September 28, CSPC PHARMA announced that its developed SYS 6077 injection has received a drug clinical trial approval notice issued by China's National Medical Products Administration, allowing clinical trials to be conducted in China. The approved clinical indication this time is advanced malignant tumors. The approval of clinical trials for this product marks an important step for the group in mRNA technology and tumor immunology, and it is expected to provide a brand-new treatment option for patients with malignant tumors in the future.